Comprehensive medication guide to Dhivy including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Covered by some Medicare Part D and commercial insurance plans; copay typically $20–$60 depending on formulary tier. Prior authorization may be required. Medicare Part D 2026 out-of-pocket cap is $2,100 annually.
Estimated Cash Pricing
$405 retail for 90 tablets (25 mg/100 mg); as low as $130 with a GoodRx coupon for a 90-day supply. No generic equivalent for the functionally scored Dhivy formulation; standard generic carbidopa/levodopa IR costs as low as $9 per month.
Medfinder Findability Score
62/100
Summarize with AI
On this page
Dhivy (pronounced "divvy") is a brand-name oral tablet containing carbidopa and levodopa, manufactured by Avion Pharmaceuticals (a subsidiary of Alora Pharmaceuticals). It is FDA-approved for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism caused by carbon monoxide or manganese intoxication.
What makes Dhivy unique is its innovative tablet design: three functional score lines allow the tablet to be snapped cleanly into four equal segments. Each full tablet contains 25 mg carbidopa and 100 mg levodopa. Each quarter segment contains 6.25 mg carbidopa and 25 mg levodopa — the smallest precisely doseable unit of carbidopa/levodopa currently available in the U.S. market.
The FDA approved Dhivy in November 2021 under NDA 214869 via the 505(b)(2) pathway, and it became commercially available in February 2022. As of 2026, there is no FDA-approved generic that replicates Dhivy's functionally scored design.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Parkinson's disease destroys the dopamine-producing neurons in the substantia nigra region of the brain. Dopamine is a neurotransmitter essential for coordinated movement, and its depletion causes the hallmark motor symptoms of Parkinson's — tremor, rigidity, bradykinesia, and balance problems.
Levodopa (the active ingredient in Dhivy) is a natural precursor of dopamine that crosses the blood-brain barrier. Once in the brain, levodopa is converted to dopamine, replenishing the depleted supply. Carbidopa — the second ingredient — blocks dopa decarboxylase enzyme activity outside the brain, preventing levodopa from being prematurely converted to dopamine in the bloodstream. This allows more levodopa to reach the brain, requires lower doses, and significantly reduces peripheral side effects like nausea.
Dhivy's unique four-segment design enables dose adjustments in 6.25/25 mg increments — clinically valuable for patients who need fine-tuned levodopa titration to minimize motor fluctuations, manage dyskinesia, or start with the smallest effective dose early in their disease.
25 mg/100 mg — Tablet, functionally scored (4 segments)
Each tablet has 3 functional score lines dividing it into 4 equal segments. Full tablet: 25 mg carbidopa/100 mg levodopa. Quarter segment: 6.25 mg carbidopa/25 mg levodopa.
Dhivy is not on an official FDA or ASHP drug shortage list as of 2026. Its immediate-release formulation is generally stable. However, because it is a specialty brand-name product from a smaller manufacturer (Avion Pharmaceuticals), it is not stocked at every pharmacy. Patients in some regions may need to search multiple pharmacies or request a special order.
The broader carbidopa/levodopa market has faced significant supply disruptions: extended-release formulations remain on the ASHP shortage list, and orally disintegrating tablets have been effectively discontinued. Immediate-release tablets — including Dhivy — are more stable but may still require proactive pharmacy searching.
Use medfinder to quickly locate pharmacies near you that have Dhivy in stock. medfinder contacts pharmacies on your behalf, saving you hours of phone calls. Start your search 10-14 days before you run out.
Dhivy (carbidopa/levodopa) is not a controlled substance, so it can be prescribed by any licensed healthcare provider without special DEA registration. The prescribers most commonly involved in Dhivy prescribing include specialists and primary care providers who manage Parkinson's disease patients.
Because Dhivy is not a controlled substance, it can also be prescribed via telehealth in most states. Several telehealth platforms now offer neurology and movement disorder consultations, expanding access for patients in rural areas or those with limited mobility.
No. Dhivy (carbidopa/levodopa) is not a controlled substance and is not scheduled by the DEA under the Controlled Substances Act. This means Dhivy can be prescribed by any licensed healthcare provider — including primary care physicians, nurse practitioners, and physician assistants — without requiring special DEA registration or prescribing authority.
Because Dhivy is not a controlled substance, prescriptions are not limited to a 30-day supply, early refills are not subject to DEA restrictions, and it can be prescribed via telehealth without the additional requirements that apply to Schedule II medications. Patients may also request 90-day supplies, which can improve adherence and reduce the frequency of the pharmacy search for this specialty product.
Common side effects include:
Serious side effects — contact your doctor promptly:
Know what you need? Skip the search.
Generic carbidopa/levodopa IR
Same active ingredients as Dhivy in 25/100 mg strength, available from multiple manufacturers (Teva, Amneal, Sun Pharma). As low as $9/month with GoodRx. Does not offer Dhivy's precise four-segment scoring.
Rytary (carbidopa/levodopa ER capsules)
Extended-release carbidopa/levodopa for longer-lasting symptom control. Requires dose conversion when switching. $800-$1,500/month without insurance; requires prior authorization.
Crexont (carbidopa/levodopa ER)
FDA-approved 2024; multi-bead ER technology enabling twice-daily dosing. Brand-only, ~$500-$700/month. Requires prior authorization and dose conversion.
Pramipexole (Mirapex)
Non-ergoline dopamine agonist for early Parkinson's disease or as adjunct to levodopa. Generic available; different mechanism than carbidopa/levodopa.
Ropinirole (Requip)
Non-ergoline dopamine agonist for early PD or adjunct therapy. Generic available. Less potent than levodopa for motor symptom control in moderate-advanced PD.
Prefer Dhivy? We can find it.
Nonselective MAO inhibitors (phenelzine, tranylcypromine, linezolid)
majorAbsolutely contraindicated. Combination can cause hypertensive crisis. Must stop MAOIs at least 14 days before starting Dhivy.
Antipsychotics and dopamine D2 antagonists (haloperidol, risperidone, metoclopramide)
majorBlock dopamine receptors, counteracting Dhivy's therapeutic effect and worsening Parkinson's symptoms.
Selegiline (selective MAO-B inhibitor)
moderateConcomitant use can cause severe orthostatic hypotension. Monitor blood pressure closely.
Iron supplements and multivitamins containing iron
moderateIron chelates with carbidopa and levodopa, reducing absorption. Space iron at least 2 hours before or after Dhivy.
Antihypertensive medications
moderateAdditive blood pressure lowering effect. Monitor for symptomatic hypotension.
High-protein diet
moderateDietary amino acids compete with levodopa for gut absorption and brain transport. May reduce medication efficacy.
Isoniazid
moderateMay reduce levodopa effectiveness. Monitor for worsening Parkinson's symptoms.
Dhivy represents a meaningful innovation in carbidopa/levodopa delivery for Parkinson's disease. Its unique four-segment scoring system enables precision dosing in 6.25/25 mg increments that standard generic tablets simply cannot reliably match. For patients managing motor fluctuations, starting on minimal doses, or dealing with swallowing difficulties, Dhivy's design can make a genuine clinical difference.
The key challenges with Dhivy in 2026 are access-related: it is a brand-name-only product not stocked at every pharmacy, and its cost is higher than generic carbidopa/levodopa alternatives. The good news is that these challenges are manageable with the right tools — savings programs, GoodRx coupons, and proactive pharmacy searching can significantly reduce the burden. The 2026 FDA vitamin B6 labeling update is also important for all patients on long-term carbidopa/levodopa therapy.
If you need help finding Dhivy at a pharmacy near you, use medfinder to search pharmacies in your area. medfinder contacts pharmacies on your behalf, giving you results by text — no hours of phone calls required. Work closely with your neurologist to find the right dose and formulation, and never stop carbidopa/levodopa abruptly.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini